| Leal Hsiao, MD | |
|
3720 Farragut Ave Fl 2, Kensington, MD 20895-2152 | |
| (301) 949-4242 | |
| Not Available |
| Full Name | Leal Hsiao |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 18 Years |
| Location | 3720 Farragut Ave Fl 2, Kensington, Maryland |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1982804241 | NPI | - | NPPES |
| 110085418A | Medicaid | MA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | C130807 (California) | Secondary |
| 207Q00000X | Family Medicine | 243268 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sibley Memorial Hospital | Washington, DC | Hospital |
| Johns Hopkins Hospital, The | Baltimore, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Johns Hopkins Community Physicians | 8325943707 | 568 |
News Archive
On October 24, 2019, cystic fibrosis (CF) patients rejoiced at the news that three years of talks between the UK's National Institute for Health and Care Excellence (NICE) and Vertex Pharmaceuticals had succeeded in a compromise which could see about 5,000 patients gaining access to a potentially life-saving drug called Orkambi within the next month. Orkambi is perceived to be a ‘wonder drug' because it helps these patients to breathe easier and better, and can be started as young as two years.
Researchers have warned that the United States has not yet reached the necessary thresholds for achieving population immunity against severe acute respiratory coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).
NovaSterilis today received a $100,000 Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) for developing a supercritical CO2 process to sterilize absorbable sutures and advanced biomaterials. The grant funds a collaboration with Chih-Chang Chu Ph.D, a pioneer in absorbable polymer development at Cornell University.
The University of Chicago Medicine Comer Children's Hospital has become the first in Illinois to offer pioneering, targeted, high-dose, intravenous radiation therapy for relapsed neuroblastoma and other difficult-to-treat cancers.
Cephalon, Inc. today announced that it and its wholly-owned subsidiary CIMA LABS INC. have filed a lawsuit in U.S. District Court in Delaware against Watson Pharmaceuticals, Inc. and its wholly-owned subsidiary, Watson Laboratories, Inc., for infringement of U.S. Patent Nos. 6,200,604 and 6,974,590, which cover methods of use for the Cephalon product FENTORA(R) (fentanyl buccal tablet) [C-II].
› Verified 7 days ago
| Entity Name | Johns Hopkins Community Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255359972 PECOS PAC ID: 8325943707 Enrollment ID: O20040130000162 |
News Archive
On October 24, 2019, cystic fibrosis (CF) patients rejoiced at the news that three years of talks between the UK's National Institute for Health and Care Excellence (NICE) and Vertex Pharmaceuticals had succeeded in a compromise which could see about 5,000 patients gaining access to a potentially life-saving drug called Orkambi within the next month. Orkambi is perceived to be a ‘wonder drug' because it helps these patients to breathe easier and better, and can be started as young as two years.
Researchers have warned that the United States has not yet reached the necessary thresholds for achieving population immunity against severe acute respiratory coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).
NovaSterilis today received a $100,000 Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) for developing a supercritical CO2 process to sterilize absorbable sutures and advanced biomaterials. The grant funds a collaboration with Chih-Chang Chu Ph.D, a pioneer in absorbable polymer development at Cornell University.
The University of Chicago Medicine Comer Children's Hospital has become the first in Illinois to offer pioneering, targeted, high-dose, intravenous radiation therapy for relapsed neuroblastoma and other difficult-to-treat cancers.
Cephalon, Inc. today announced that it and its wholly-owned subsidiary CIMA LABS INC. have filed a lawsuit in U.S. District Court in Delaware against Watson Pharmaceuticals, Inc. and its wholly-owned subsidiary, Watson Laboratories, Inc., for infringement of U.S. Patent Nos. 6,200,604 and 6,974,590, which cover methods of use for the Cephalon product FENTORA(R) (fentanyl buccal tablet) [C-II].
› Verified 7 days ago
| Entity Name | Professional Services Of Holy Cross |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487692828 PECOS PAC ID: 3779516992 Enrollment ID: O20050916000745 |
News Archive
On October 24, 2019, cystic fibrosis (CF) patients rejoiced at the news that three years of talks between the UK's National Institute for Health and Care Excellence (NICE) and Vertex Pharmaceuticals had succeeded in a compromise which could see about 5,000 patients gaining access to a potentially life-saving drug called Orkambi within the next month. Orkambi is perceived to be a ‘wonder drug' because it helps these patients to breathe easier and better, and can be started as young as two years.
Researchers have warned that the United States has not yet reached the necessary thresholds for achieving population immunity against severe acute respiratory coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).
NovaSterilis today received a $100,000 Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) for developing a supercritical CO2 process to sterilize absorbable sutures and advanced biomaterials. The grant funds a collaboration with Chih-Chang Chu Ph.D, a pioneer in absorbable polymer development at Cornell University.
The University of Chicago Medicine Comer Children's Hospital has become the first in Illinois to offer pioneering, targeted, high-dose, intravenous radiation therapy for relapsed neuroblastoma and other difficult-to-treat cancers.
Cephalon, Inc. today announced that it and its wholly-owned subsidiary CIMA LABS INC. have filed a lawsuit in U.S. District Court in Delaware against Watson Pharmaceuticals, Inc. and its wholly-owned subsidiary, Watson Laboratories, Inc., for infringement of U.S. Patent Nos. 6,200,604 and 6,974,590, which cover methods of use for the Cephalon product FENTORA(R) (fentanyl buccal tablet) [C-II].
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Leal Hsiao, MD 3720 Farragut Ave Fl 2, Kensington, MD 20895-2152 Ph: (301) 949-4242 | Leal Hsiao, MD 3720 Farragut Ave Fl 2, Kensington, MD 20895-2152 Ph: (301) 949-4242 |
News Archive
On October 24, 2019, cystic fibrosis (CF) patients rejoiced at the news that three years of talks between the UK's National Institute for Health and Care Excellence (NICE) and Vertex Pharmaceuticals had succeeded in a compromise which could see about 5,000 patients gaining access to a potentially life-saving drug called Orkambi within the next month. Orkambi is perceived to be a ‘wonder drug' because it helps these patients to breathe easier and better, and can be started as young as two years.
Researchers have warned that the United States has not yet reached the necessary thresholds for achieving population immunity against severe acute respiratory coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).
NovaSterilis today received a $100,000 Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) for developing a supercritical CO2 process to sterilize absorbable sutures and advanced biomaterials. The grant funds a collaboration with Chih-Chang Chu Ph.D, a pioneer in absorbable polymer development at Cornell University.
The University of Chicago Medicine Comer Children's Hospital has become the first in Illinois to offer pioneering, targeted, high-dose, intravenous radiation therapy for relapsed neuroblastoma and other difficult-to-treat cancers.
Cephalon, Inc. today announced that it and its wholly-owned subsidiary CIMA LABS INC. have filed a lawsuit in U.S. District Court in Delaware against Watson Pharmaceuticals, Inc. and its wholly-owned subsidiary, Watson Laboratories, Inc., for infringement of U.S. Patent Nos. 6,200,604 and 6,974,590, which cover methods of use for the Cephalon product FENTORA(R) (fentanyl buccal tablet) [C-II].
› Verified 7 days ago
Dr. Caesar Augustus Junker, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 10810 Connecticut Avenue, Kensington, MD 20895 Phone: 301-929-7100 Fax: 301-929-7114 | |
Alison Anna Sikirica, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 10540 Connecticut Ave, Kensington, MD 20895 Phone: 301-949-0030 Fax: 301-949-0033 | |
Janet Kaye Oneal, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 9709 Stoneybrook Drive, Office And Residence, Kensington, MD 20895 Phone: 301-589-7441 Fax: 301-495-8991 | |
Audrey Nnoli, NP Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 10810 Connecticut Ave, Kensington, MD 20895 Phone: 301-929-7275 | |
Dr. Sharmila Aryal, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 10810 Connecticut Ave, Kaiser Permanente Kensington Medical Center, Kensington, MD 20895 Phone: 301-929-7100 | |
Dr. Deborah S Belsky, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 10810 Connecticut Ave, Kensington Medical Center, Kensington, MD 20895 Phone: 301-929-7100 | |
Dr. John Clark Lucas, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 10810 Connecticut Avenue, Kensington, MD 20895 Phone: 301-929-7100 Fax: 301-929-7114 |